BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1373 related articles for article (PubMed ID: 28887948)

  • 1. Psoriasis pathogenesis and the development of novel targeted immune therapies.
    Hawkes JE; Chan TC; Krueger JG
    J Allergy Clin Immunol; 2017 Sep; 140(3):645-653. PubMed ID: 28887948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis.
    Hawkes JE; Yan BY; Chan TC; Krueger JG
    J Immunol; 2018 Sep; 201(6):1605-1613. PubMed ID: 30181299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of emerging immunotherapies in psoriasis.
    Yiu ZZ; Warren RB
    Immunotherapy; 2015; 7(2):119-33. PubMed ID: 25713988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
    Jeon C; Sekhon S; Yan D; Afifi L; Nakamura M; Bhutani T
    Hum Vaccin Immunother; 2017 Oct; 13(10):2247-2259. PubMed ID: 28825875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of IL 23 in the treatment of psoriasis.
    Puig L
    Expert Rev Clin Immunol; 2017 Jun; 13(6):525-534. PubMed ID: 28165883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors.
    Dong J; Goldenberg G
    Cutis; 2017 Feb; 99(2):123-127. PubMed ID: 28319618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study.
    Torres T; Puig L; Vender R; Yeung J; Carrascosa JM; Piaserico S; Gisondi P; Lynde C; Ferreira P; Bastos PM; Dauden E; Leite L; Valerio J; Del Alcázar-Viladomiu E; Rull EV; Llamas-Velasco M; Pirro F; Messina F; Bruni M; Licata G; Ricceri F; Nidegger A; Hugo J; Mufti A; Daponte AI; Teixeira L; Balato A; Romanelli M; Prignano F; Gkalpakiotis S; Conrad C; Lazaridou E; Rompoti N; Papoutsaki M; Nogueira M; Chiricozzi A
    Am J Clin Dermatol; 2022 Nov; 23(6):891-904. PubMed ID: 35976568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenic role of IL-17 in psoriasis and psoriatic arthritis.
    Chiricozzi A
    Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():9-20. PubMed ID: 25398488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti IL-17 in psoriasis.
    Ly K; Smith MP; Thibodeaux Q; Reddy V; Liao W; Bhutani T
    Expert Rev Clin Immunol; 2019 Nov; 15(11):1185-1194. PubMed ID: 31603358
    [No Abstract]   [Full Text] [Related]  

  • 10. IL-17 targeted therapies for psoriasis.
    Chiricozzi A; Krueger JG
    Expert Opin Investig Drugs; 2013 Aug; 22(8):993-1005. PubMed ID: 23731078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis.
    Gisondi P; Geat D; Pizzolato M; Girolomoni G
    Curr Opin Pharmacol; 2019 Jun; 46():90-99. PubMed ID: 31212119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Biologic Agents Targeting Interleukin-23 and Interleukin-17 for Moderate-to-Severe Psoriasis.
    Chen Z; Gong Y; Shi Y
    Clin Drug Investig; 2017 Oct; 37(10):891-899. PubMed ID: 28755058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis.
    Sakkas LI; Zafiriou E; Bogdanos DP
    Front Pharmacol; 2019; 10():872. PubMed ID: 31447673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next-generation biologics in the management of plaque psoriasis: a literature review of IL-17 inhibition.
    Yamauchi PS; Bagel J
    J Drugs Dermatol; 2015 Mar; 14(3):244-53. PubMed ID: 25738846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis.
    Mease PJ
    Curr Opin Rheumatol; 2015 Mar; 27(2):127-33. PubMed ID: 25599143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin 17A: toward a new understanding of psoriasis pathogenesis.
    Lynde CW; Poulin Y; Vender R; Bourcier M; Khalil S
    J Am Acad Dermatol; 2014 Jul; 71(1):141-50. PubMed ID: 24655820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new class of biologic agents facing the therapeutic paradigm in psoriasis: anti-IL-23 agents.
    Tonini A; Gualtieri B; Panduri S; Romanelli M; Chiricozzi A
    Expert Opin Biol Ther; 2018 Feb; 18(2):135-148. PubMed ID: 29103330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The plot thickens while the scope broadens: a holistic view on IL-17 in psoriasis and other inflammatory disorders.
    Schön MP
    Exp Dermatol; 2014 Nov; 23(11):804-6. PubMed ID: 25219805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of IL-17 in psoriasis.
    Malakouti M; Brown GE; Wang E; Koo J; Levin EC
    J Dermatolog Treat; 2015 Feb; 26(1):41-4. PubMed ID: 24552504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-17 and innate immunity in infections and chronic inflammation.
    Isailovic N; Daigo K; Mantovani A; Selmi C
    J Autoimmun; 2015 Jun; 60():1-11. PubMed ID: 25998834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 69.